Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2021-09-24 Capital/Financing Update
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text specifically mentions the closing of a public offering of common stock and pre-funded warrants, and includes a press release as an exhibit. The document is short (3838 characters) and focuses on a financing event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an Annual Report, Earnings Release, or other report type. Therefore, the correct classification is CAP with high confidence.
2021-09-24 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock and pre-funded warrants by Leap Therapeutics, Inc. It includes detailed offering terms, underwriting information, risk factors, use of proceeds, and legal matters. The document is a registration statement supplement for a securities offering, not a financial report, earnings release, or management discussion. It is a capital markets document related to fundraising and issuance of securities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2021-09-22 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an underwritten public offering of common stock and pre-funded warrants, including details about the underwriting agreement, offering price, number of shares, and use of proceeds. It also includes a press release about pricing the offering. This is a clear update on the company's capital raising activities and financing transactions. The document is not an annual or quarterly report, audit report, or earnings release. It is not a proxy statement, voting results, or management change announcement. The primary focus is on financing and capital structure update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9520 characters) and detailed content support that this is a substantive filing, not just an announcement of a report. Confidence is high given the explicit description of the underwriting agreement and offering details.
2021-09-22 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement and accompanying prospectus related to a securities offering by Leap Therapeutics, Inc. It includes sections such as "Prospectus Supplement Summary," "Risk Factors," "Use of Proceeds," and detailed descriptions of securities offered, underwriting, legal matters, and incorporation by reference of other SEC filings. The document references the SEC registration statement and shelf registration process, typical of capital raising documents. It does not contain financial statements or earnings data but focuses on the terms and details of a securities offering. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a full prospectus supplement. Therefore, the correct classification is CAP with high confidence.
2021-09-21 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It announces a proposed underwritten public offering of common stock and pre-funded warrants, and references a press release and a corporate presentation. The content focuses on a financing event rather than a full financial report or earnings release. The document length is 4133 characters, which is relatively short and typical for an 8-K filing announcing a capital raising event. Therefore, the filing type corresponds to a Capital/Financing Update (CAP).
2021-09-21 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release and a poster presentation related to updated clinical data presented at a medical conference. It does not contain comprehensive financial statements or detailed financial analysis. The document length is 4148 characters, which is relatively short and consistent with a current report rather than a full financial report. The content is primarily an announcement of an event and related exhibits, not a full report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-09-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.